Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR339375 in Alport syndrome
CTR20201390Phase 2Terminated
- Sponsor
- Sanofi
- Start
- Aug 2020
- Modality
- Vaccine mRNA → mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of lademirsen in Alport syndrome, sponsored by Sanofi. Started Aug 2020; status: terminated.
02
Drugs
lademirsen
03
Conditions
Alport syndrome
Beyond the preview
Go deeper on CTR20201390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201390.